Company: CDT
Filing Date: 2025-07-08
Form Type: DEF 14A
Source: 0001641172-25-018242
Chunk: 12

Company: CDT Equity Inc.
Filing Date: 2025-07-08
Form: DEF 14A
Chunk 12
---
; Vice President Research and Development at Pharmacia Corporation from 2002-2003; product team leader at Pharmacia and Eli Lilly and Company from 1998 to 2002; director of Lilly Center for Women’s Health from 1996-1999; and clinical research physician at Eli Lilly from 1994 through 1996. In October 2021, Dr. Lewis-Hall became a member of the board of directors for Pyxis Oncology (Nasdaq: PYXS), (where she serves as a member of the nominating and corporate governance committee); she served as a member of the board of directors for Milliken & Company from July 2019 until 2025, as a member of the audit and human resources and compensation committees; and as a member of the board of directors of Springworks Therapeutics, Inc. (NasdaqGS: SWTX) from 2017 to July 2025, where she serves as the chair of the nominating and governance committee and as a member of the audit committee. Dr. Lewis-Hall served as a member of the board of directors for Exact Sciences Corporation (Nasdaq: EXAS) from April 2020 to June 2024 where she served as a member of the human capital and innovation, technology and pipeline committees; a member of 1lifehealthcare, Inc. (Nasdaq: ONEM) board from November 2019 to 2023, serving as a member of the nominating and corporate governance committee; she also served as a member of the board of directors for Tenet Healthcare Corporation (NYSE: THC) from 2014 to 2017.

| 6 |

Dr. Lewis-Hall holds an M.D. from Howard University College of Medicine and a B.A. in natural sciences from the Johns Hopkins University. The Company believes Dr. Lewis-Hall is qualified to serve on the Board based on her expertise and experience in the biopharmaceutical industry and her leadership experience as a senior executive at various biopharmaceutical companies.

James Bligh.Mr. Bligh has served as a member of our Board since September 2023, and also currently serves as our Interim Chief Financial Officer. He was a co-founder of Conduit Pharmaceuticals Limited in 2019 and has served as a member of its board of directors since its inception. From 2008 to 2019, Mr. Bligh worked closely with investment vehicle Corvus Capital Limited, including as a Partner, where